Hester Biosciences (Small Cap - High Growth) Share Target 2024, 2025 To 2039
|
Hester Biosciences Limited |
|||
|
Price: ₹2,382.05 | ||
| 52 Week Low: ₹1,292.85 52 Week High: ₹3,379.00 |
|||
| Market Capital: 2,026.24 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Hester Biosciences Share Price Target For 2024
- 1.1.1: Hester Biosciences Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Hester Biosciences Share Price Target For 2025
- 1.2.1: Hester Biosciences Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Hester Biosciences Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Hester Biosciences Brief Company Overview
- 4: Hester Biosciences Financial Performance
- 4.0.1: Is Hester Biosciences A Good Buy For Long Term?
To predict the Hester Biosciences's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Hester Biosciences Share Price Target For 2024
The line chart displays the monthly closing prices of Hester Biosciences with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Hester Biosciences shares in 2024, see the table below.
Hester Biosciences Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 2483.94 (+4.26%) | Price Action: 18 Nov 2024 High |
| 2024 Target 2 | 2456.73 (+3.13%) | Fibonacci Extension Level 23.60% |
| 2024 Target 1 | 2430.0 (+2%) | Price Action: 16 Dec 2024 Low |
| Current Price | 2382.05 | Hester Biosciences's share price as of 23 Dec 2024 |
| Stop Loss 1 | 2352.51 (-1.25%) | Price Action: Jun 2022 High |
| Stop Loss 2 | 2328.05 (-2.27%) | Price Action: 30 Oct 2024 Low |
| Stop Loss 3 | 2300.05 (-3.45%) | Price Action: 29 Oct 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Hester Biosciences is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹2448.31 serves as the nearest technical reference point.
Historical Returns: 3-month: -3.52% | 6-month: -0.96% | 1-year: +63.07%
Hester Biosciences Share Price Target For 2025
The line chart displays the monthly closing prices of Hester Biosciences with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Hester Biosciences shares in 2025, see the table below.
Hester Biosciences Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 3862.01 (+62.12%) | Fibonacci Extension Level 123.60% |
| 2025 Target 2 | 3770.03 (+58.26%) | Price Action: Chart |
| 2025 Target 1 | 3732.7 (+56.7%) | Fibonacci Extension Level 64.90% |
| Current Price | 2382.05 | Hester Biosciences's share price as of 23 Dec 2024 |
| Stop Loss 1 | 2073.26 (-12.97%) | Technical Indicator: MA250 |
| Stop Loss 2 | 2052.53 (-13.84%) | Price Action: Chart |
| Stop Loss 3 | 2015.58 (-15.39%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Hester Biosciences is currently trading at 52.2% of its 52-week range (₹1292.85 - ₹3379).
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: +63.07% | 3-year: -5.24% | 5-year: +66.86%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Hester Biosciences Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹2,382.05 | ||
| 2024 | ₹2,660.22 | +11.67% | ₹2,700.12 |
| 2025 | ₹4,067.90 | +52.91% | ₹4,525.81 |
| 2026 | ₹6,571.81 | +61.55% | ₹6,670.39 |
| 2027 | ₹8,335.35 | +26.83% | ₹8,460.38 |
| 2028 | ₹8,622.99 | +3.45% | ₹8,752.33 |
| 2029 | ₹9,261.11 | +7.4% | ₹9,783.13 |
| 2030 | ₹10,813.90 | +16.76% | ₹10,976.11 |
| 2031 | ₹14,755.78 | +36.45% | ₹14,977.12 |
| 2032 | ₹16,645.70 | +12.8% | ₹16,895.39 |
| 2033 | ₹15,790.84 | -5.13% | ₹17,034.58 |
| 2034 | ₹15,862.00 | +0.45% | ₹19,125.90 |
| 2035 | ₹17,559.90 | +10.7% | ₹21,217.23 |
| 2036 | ₹22,939.76 | +30.63% | ₹23,308.55 |
| 2037 | ₹24,956.05 | +8.78% | ₹25,330.39 |
| 2038 | ₹22,958.70 | -8% | ₹25,399.87 |
| 2039 | ₹21,433.27 | -6.64% | ₹27,491.19 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Hester Biosciences Brief Company Overview
Hester Biosciences Limited: A Leader in Animal Healthcare Established in 1987, Hester Biosciences Limited is a renowned manufacturer and trader of veterinary vaccines and animal health products in India and globally. The company's diverse product range caters to...
poultry, livestock, and pet healthcare. Poultry vaccines include those for Newcastle disease, infectious bronchitis, and avian encephalomyelitis, while livestock vaccines protect against goat pox, peste des petits ruminants, and contagious bovine pleuropneumonia. Beyond vaccines, Hester Biosciences offers a comprehensive suite of animal health products, such as biosecurity solutions, herbal supplements, and feed supplements. Its petcare products include gut health solutions, NSAIDs, and anti-infective formulations. The company's commitment to innovation is evident in its diagnostic kits for enzyme-linked immunosorbent assay and polymerase chain reaction.Hester Biosciences Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 2,026.24 Crore | Market valuation of Hester Biosciences's shares. |
| Revenue (TTM) | 316.4 Crore | Total revenue generated by Hester Biosciences over the past twelve months. |
| Net Income (TTM) | +23.46 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +19.64% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +7.41% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+14.3% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+100.69% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
77.65 | Company's total debt divided by total shareholder equity. |
| Total Debt | 244.02 Crore | Sum of Hester Biosciences's current & long-term financial obligations. |
| Total Cash | 16.78 Crore | Total amount of liquid funds available to Hester Biosciences. |
| Beta | 0.69 | Beta is less than 1 indicating that the Hester Biosciences's price is less volatile than the market. |
Is Hester Biosciences A Good Buy For Long Term?
Hester Biosciences, a small-cap stock with a market capitalization of ₹2,026.24 crore, presents a mixed picture for long-term investors. While its five-year return of 111.46% is impressive, and YTD return is 63.62%, the recent three-month return of -23.46% raises concerns. A significant debt of ₹244.02 crore against a cash balance of only ₹16.78 crore also warrants caution. Though its revenue grew by 14.3% quarter-over-quarter, a profit margin of only 7.41% limits its attractiveness. Therefore, it's currently an average buy, requiring closer monitoring of debt levels and profit margins before a stronger recommendation can be made.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
